NCT02656511View on ClinicalTrials.gov

"Immediate Initiation of Antiretroviral Therapy During Hyperacute HIV Infection"

PHASE4Active, not recruitingINTERVENTIONAL
Enrollment

74

Participants

Timeline

Start Date

December 31, 2015

Primary Completion Date

May 31, 2027

Study Completion Date

May 31, 2028

Conditions
HIV
Interventions
DRUG

Dolutegravir

Dolutegravir 50 mg PO daily

DRUG

Emtricitabine/Tenofovir

Emtricitabine 200 mg/Tenofovir alafenamide 25 mg PO daily

Trial Locations (1)

94110

San Francisco General Hospital, San Francisco

Sponsors
All Listed Sponsors
collaborator

ViiV Healthcare

INDUSTRY

collaborator

Gilead Sciences

INDUSTRY

lead

University of California, San Francisco

OTHER